Corpus ID: 76322784

Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery

  title={Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery},
  author={Sirada Srihirun and สิรดา ศรีหิรัญ and N. Sibmooh and ณัฐวุธ สิบหมู่},
Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery Sirada Srihirun, Nathawut Sibmooh Sirada Srihirun, Nathawut Sibmooh 1 Department of Pharmacology, Faculty of Dentistry, Mahidol University Email: 2 Department of Pharmacology, Faculty of Science, Mahidol University Email: Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery 


Thienopyridines and other ADP-receptor antagonists.
Whether individualized antiplatelet treatment incorporating different P2Y12 receptor inhibitors improves patients' clinical outcomes warrants further investigation. Expand
Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
Preclinical and clinical data on cangrelor and AZD6140 are summarized and the potential of these compounds as novel antiplatelet therapies are discussed. Expand
The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function
Cangrelor influences the ability of the active metabolites of clopidogrel or prasugrel to inhibit platelet function irreversibly, and careful consideration should be given to the timing of administration of an oral P2Y12 antagonist following cangrelor infusion. Expand
Cangrelor: a review on its mechanism of action and clinical development
An overview of the current status of knowledge on cangrelor is provided, focusing on its pharmacologic properties, clinical development and potential future applications. Expand
New P2Y12 Inhibitors
P2Y12 stabilizes the platelet aggregates and amplifies the secretion of platelet dense granules stimulated by secretion-inducing agonists, making it an attractive molecular target for therapeutic intervention and the target of efficacious antithrombotic agents. Expand
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
The data indicate that P2Y12 is targeted by ticagrelor via a mechanism that is non‐competitive with ADP, suggesting the existence of an independent receptor‐binding site for CPTPs. Expand
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Clinical studies in patients with cardiovascular disease confirmed the potent antiplatelet effect of prasugrel compared with clopidogrel and aided in dose selection for the recently completed phase 3 trial of patients with acute coronary syndrome undergoing percutaneous coronary intervention. Expand
Adverse Haematological Effects of Ticlopidine
Patients should be educated about the potential adverse effects and complications associated with ticlopidine, including possible death, and there should be careful attention to haematological monitoring to screen for and promptly detect any adverse effects. Expand
New Directions in Antiplatelet Therapy
The objective of the present manuscript is to provide an overview on the most recent advances of currently approved antiplatelet agents in the setting of ACS and PCI, as well as on emerging agents that are in clinical development. Expand
Prasugrel Versus Clopidogrel: A Comparative Examination of Local Bleeding After Dental Extraction in Patients Receiving Dual Antiplatelet Therapy.
This study is the first to analyze differences in bleeding times between clopidogrel and prasugrel treatments during dental extraction, and in general, pr asugrel is associated with a considerably longer bleeding time; nevertheless, dental extraction can be performed safely with either combination. Expand